You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TP53 mutation

Showing 1 - 25 of 4,024
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced NSCLC Trial in Jinan (almonertinib)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • Jinan, Shandong, China
    Degan Lu
Sep 12, 2023

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

NSCLC Trial in Guangzhou (Ensartinib, Bevacizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 4, 2022

Advanced Gastric Adenocarcinoma Trial in Seoul (AZD1775, paclitaxel)

Completed
  • Advanced Gastric Adenocarcinoma
  • Seoul, Korea, Republic of
    Samsung Medical center
Jun 13, 2022

Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome Trial in Boston (Data and Specimen Collection)

Recruiting
  • Li-Fraumeni Syndrome
  • +4 more
  • Data and Specimen Collection
  • Boston, Massachusetts
  • +2 more
Jan 23, 2023

NSCLC, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma Trial in Duarte (Autologous, engineered T Cells targeting

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +5 more
  • Autologous, engineered T Cells targeting TP53 R175H
  • Duarte, California
    City of Hope
May 17, 2023

Ovarian Endometrioid Tumor, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Toronto (Atezolizumab, Bevacizumab)

Recruiting
  • Ovarian Endometrioid Tumor
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Oct 21, 2021

Chronic Lymphocytic Leukemia Trial (Zebutinib&BR or Zebutinib&FCR)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Zebutinib&BR or Zebutinib&FCR
  • (no location specified)
Jul 27, 2021

Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of

Not yet recruiting
  • Ovarian Cancer
  • Patients with Ovarian cancer and pap test available
  • Milan, Italy
  • +1 more
Mar 19, 2021

Patogenic Mutation in 5 Genes

Completed
  • Colorectal Cancer
  • +5 more
  • co-occuring mutation
  • Jakarta, ALL, Indonesia
    Vania Myralda Giamour Marbun
Jul 21, 2021

Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

Not yet recruiting
  • Hematologic Malignancy
  • +21 more
  • (no location specified)
Feb 9, 2023

Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)

Completed
  • Leukemia, Lymphocytic, Chronic
  • Dresden, Germany
  • +10 more
Jan 13, 2023

Colorectal Cancer Metastatic, Colorectal Cancer Stage IV, TP53 Gene Mutation Trial in Bergen (Cyclophosphamide)

Terminated
  • Colorectal Cancer Metastatic
  • +2 more
  • Bergen, Norway
    Haukeland University Hospital
Jan 20, 2021

Chronic Lymphocytic Leukemia (CLL) Trial in Worldwide (Obinutuzumab, Venetoclax, Fludarabine)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Aurora, Colorado
  • +55 more
Jan 30, 2023

Chronic Lymphocytic Leukemia Trial in Germany (Obinutuzumab, Venetoclax, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Bad Saarow, Germany
  • +29 more
May 4, 2022

Adult Solid Tumor, Bladder Carcinoma, Colon Carcinoma Trial in Duarte (Laboratory Biomarker Analysis, Modified Vaccinia Virus

Active, not recruiting
  • Adult Solid Neoplasm
  • +16 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Myeloid Leukemia, MDS Trial (IFN-?)

Not yet recruiting
  • Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Nov 15, 2023

Patients With Breast Cancer and Pathogenic Variants of TP53

Completed
  • Breast Cancer
  • +3 more
  • No intervention in this study
  • São Paulo, Brazil
    ICESP
Aug 5, 2022

Clinical and Genetic Studies of Li-Fraumeni Syndrome

Recruiting
  • Li-Fraumeni Syndrome
  • +2 more
    • Bethesda, Maryland
    • +1 more
    Jan 25, 2023

    Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

    Recruiting
    • Solid Tumor, Adult
    • +6 more
    • TP53-EphA-2-CAR-DC
    • +3 more
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinsese PLA Gereral Hospital
    Nov 29, 2022

    Non-small Cell Carcinoma, EGFR Gene Mutation Trial in Guangzhou (Osimertinib 80 MG [Tagrisso], Pemetrexed 500 MG Injection,

    Not yet recruiting
    • Non-small Cell Carcinoma
    • EGFR Gene Mutation
    • Osimertinib 80 MG [Tagrisso]
    • +2 more
    • Guangzhou, Guangdong, China
      Department of Medical Oncology,Cancer Center of Sun Yat-Sen Univ
    Jan 3, 2021

    Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Shanghai, Shanhai, China
      Ruijin Hospital
    Sep 29, 2023

    Li-Fraumeni Syndrome, Li-Fraumeni-Like Syndrome Trial in Philadelphia (No Intervention)

    Recruiting
    • Li-Fraumeni Syndrome
    • Li-Fraumeni-Like Syndrome
    • No Intervention
    • Philadelphia, Pennsylvania
    • +1 more
    Jan 2, 2022

    Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)

    Not yet recruiting
    • Lymphoma, Mantle-Cell
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Nov 14, 2023

    NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

    Not yet recruiting
    • NSCLC
    • Non-small Cell Lung Cancer
    • Apatinib + Fluzoparib
    • Apatinib + Fluzoparib + Adebrelimab
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 27, 2023